FDA 483 OBSERVATION · #1288 OF 1,932 MOST-CITED

Who must report - manufacturer

FDA cited this observation 11 times across 11 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Biologics11
BY FISCAL YEAR
FY20261
FY20251
FY20242
FY20231
FY20221
FY20201
FY20192
FY20181
FY20161

How FDA worded it — real examples

Failure to submit biological deviation.

CSL Behring GmbH · Marburg · Biologics · 2026-02-18

Failure to submit biological deviation reports.

Octapharma Dessau GmbH · Dessau-Roslau · Biologics · 2024-11-08

Failure to submit a biological deviation reports.

Inova Health Care Services · Sterling, Virginia · Biologics · 2024-09-04

Failure to submit a biological deviation report.

Janssen Pharmaceuticals Inc. · Raritan, New Jersey · Biologics · 2023-12-14

Failure to submit a biological deviation report.

North Shore University Hospital Northwell Health · Manhasset, New York · Biologics · 2023-04-26

Failure to submit biological deviation reports.

Cedars-Sinai Medical Center · West Hollywood, California · Biologics · 2022-08-26

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Biologics industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →